{"id":"systemic-corticosteroids-methotrexate","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (opportunistic and bacterial)"},{"rate":null,"effect":"Bone loss / osteoporosis"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Mood changes / insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Systemic corticosteroids reduce inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation. Methotrexate acts as a disease-modifying antirheumatic drug (DMARD) by inhibiting dihydrofolate reductase, reducing cell proliferation and immune responses. Together, they provide complementary immunosuppressive effects for treating autoimmune and inflammatory conditions.","oneSentence":"This combination suppresses immune system activity through corticosteroid-mediated anti-inflammatory effects and methotrexate-induced immunosuppression via folate antagonism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:40.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"},{"name":"Vasculitis"},{"name":"Other autoimmune inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT01180361","phase":"","title":"Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06768294","phase":"PHASE2","title":"Baricitinib in CPPD - the BAPTIST Study","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2025-01","conditions":"Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis","enrollment":32},{"nctId":"NCT01903317","phase":"","title":"Evaluation of Vitamin D Levels in Psoriasis Patients","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2013-06","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT02837965","phase":"","title":"Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2013-09-26","conditions":"Bullous Pemphigoid","enrollment":149},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT04726553","phase":"EARLY_PHASE1","title":"Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE","status":"UNKNOWN","sponsor":"Oklahoma Medical Research Foundation","startDate":"2021-01-20","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":20},{"nctId":"NCT05674695","phase":"","title":"Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy","status":"RECRUITING","sponsor":"Fundación Academia Española de Dermatología","startDate":"2019-01-01","conditions":"Dermatitis, Atopic","enrollment":2500},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT05120687","phase":"","title":"Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-10-15","conditions":"Vogt Koyanagi Harada Disease (VKH)","enrollment":200},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT03606707","phase":"EARLY_PHASE1","title":"Efficacy of Fluoroscopic Guided Atlantoaxial Joint Injection on Head and Neck Pain and Sleep Quality in RA Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-06-01","conditions":"Pain, Head, Sleep Disturbance","enrollment":60},{"nctId":"NCT00392834","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Lymphoma","enrollment":34},{"nctId":"NCT00096135","phase":"NA","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Leukemia","enrollment":168},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT00642460","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":112},{"nctId":"NCT00084838","phase":"PHASE2","title":"Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2003-02","conditions":"Central Nervous System Tumor, Pediatric","enrollment":25},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT01079988","phase":"PHASE4","title":"Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-02","conditions":"Psoriasis","enrollment":41},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT00002524","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1993-06","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00307671","phase":"PHASE4","title":"Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-07","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Systemic corticosteroids/methotrexate","genericName":"Systemic corticosteroids/methotrexate","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination suppresses immune system activity through corticosteroid-mediated anti-inflammatory effects and methotrexate-induced immunosuppression via folate antagonism. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Vasculitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}